Swiss biotech Roivant accepts $3 billion for stake in business

6 September 2019
roivant_logo_big

In a bold move to broaden its interests overseas, Japanese drugmaker Sumitomo Dainippon (TYO: 4506) has agreed to pay $3 billion for a chunk of Roivant Sciences’ biopharmaceutical units, plus a 10% share in the rest of the company.

The deal will involve the creation of a novel and broad Alliance to include the transfer of Roivant’s ownership interests in five of its biopharmaceutical companies, with an option to acquire up to six more.

The agreement also provides access to Roivant’s proprietary technology platforms, DrugOme and Digital Innovation, and Sumitomo will take a 10% stake in the rest of Roivant.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology